Sam Park - Sight Sciences Chief Officer
| SGHT Stock | USD 2.46 0.07 2.77% |
Insider
Sam Park is Chief Officer of Sight Sciences
| Age | 63 |
| Phone | 877 266 1144 |
| Web | https://www.sightsciences.com |
Sam Park Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sam Park against Sight Sciences stock is an integral part of due diligence when investing in Sight Sciences. Sam Park insider activity provides valuable insight into whether Sight Sciences is net buyers or sellers over its current business cycle. Note, Sight Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sight Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sam Park over three months ago Acquisition by Sam Park of 6000 shares of Sight Sciences at 1.96 subject to Rule 16b-3 | ||
Sam Park over three months ago Disposition of 3403 shares by Sam Park of Sight Sciences at 6.08 subject to Rule 16b-3 | ||
Sam Park over a year ago Acquisition by Sam Park of 151869 shares of Sight Sciences subject to Rule 16b-3 | ||
Sam Park over a year ago Sale by Sam Park of 5443 shares of Sight Sciences |
Sight Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1941) % which means that it has lost $0.1941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4536) %, meaning that it created substantial loss on money invested by shareholders. Sight Sciences' management efficiency ratios could be used to measure how well Sight Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Colleran | Anika Therapeutics | 52 | |
| Erik Mickelson | Paragon 28 | 42 | |
| Anthony Semedo | Artivion | 69 | |
| John Davis | Artivion | 60 | |
| S Mansbach | Avanos Medical | N/A | |
| Paul Verrastro | CVRx Inc | 61 | |
| Lisa Paul | Pulmonx Corp | 61 | |
| Mark Saxton | Neuropace | 59 | |
| John Wilson | Rapid Micro Biosystems | 57 | |
| Thomas Ackerman | Artivion | 66 | |
| MD ODonnell | Tactile Systems Technology | N/A | |
| Victoria Vezina | Rapid Micro Biosystems | 56 | |
| Martha Morrell | Neuropace | 67 | |
| Marna Borgstrom | Artivion | 67 | |
| Christopher Belfiore | Varex Imaging Corp | N/A | |
| Jonathan Paris | Rapid Micro Biosystems | 48 | |
| Kerr Holbrook | Avanos Medical | 58 | |
| Anne Nunes | Anika Therapeutics | 55 | |
| Daniel Bevevino | Artivion | 61 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Moji James | Avanos Medical | N/A | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.19 |
Sight Sciences Leadership Team
Elected by the shareholders, the Sight Sciences' board of directors comprises two types of representatives: Sight Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sight. The board's role is to monitor Sight Sciences' management team and ensure that shareholders' interests are well served. Sight Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sight Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, VP Operations | ||
| Stacie Rodgers, VP HR | ||
| John Liu, VP Access | ||
| Stephen JD, Secretary | ||
| Reay MD, Chief Officer | ||
| Sam Park, Chief Officer | ||
| John Ordway, VP Operations | ||
| Brenton Taylor, Executive Operations | ||
| Jim Rodberg, VP Controller | ||
| Matthew Link, Chief Officer | ||
| Jeremy JD, Chief Officer | ||
| Paul Badawi, President, CoFounder | ||
| Steve Tamayo, VP Officer | ||
| Tom Huang, Head Development | ||
| Alison Bauerlein, CFO Treasurer | ||
| Reay Brown, Chief Officer | ||
| David MD, CTO Founder | ||
| Jesse Selnick, Chief Officer | ||
| Jeremy Hayden, Chief Officer | ||
| Manohar Raheja, Executive Development |
Sight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sight Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 40.7 M | ||||
| Shares Outstanding | 50.4 M | ||||
| Shares Owned By Insiders | 20.24 % | ||||
| Shares Owned By Institutions | 53.22 % | ||||
| Number Of Shares Shorted | 1.2 M | ||||
| Price To Book | 1.34 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sight Stock Analysis
When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.